Study of ALTO-300 in MDD
ClinicalTrials.gov ID NCT05922878 · A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
At a glance
- Status
- Recruiting
- Condition
- Major Depressive Disorder
- Phase
- Phase 2
- Ages
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Not accepted
- What is being studied
- ALTO-300 (drug); Placebo (drug)
- Sponsor
- Alto Neuroscience
- Target enrollment
- 325 participants
- Study sites
- 31 open in Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Massachusetts, Minnesota, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Texas, Virginia
- Start date
- 2023-06-08
- Primary completion
- 2026-12
Common questions
Is NCT05922878 still recruiting?
ClinicalTrials.gov lists this trial as recruiting (checked 22 November 2026). It has 31 open or upcoming sites.
Who can take part in NCT05922878?
The record lists people aged 18 to 70 years with major depressive disorder. The study team decides who is eligible, and the full criteria are on this page and in the official record.
Where is NCT05922878 running?
31 sites in Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Massachusetts, Minnesota, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Texas, Virginia, according to ClinicalTrials.gov.
What is being studied in NCT05922878?
It is a Phase 2 trial. The record lists these interventions: ALTO-300 and Placebo. The sponsor is Alto Neuroscience.
How many people will NCT05922878 enroll?
The record gives a target of 325 participants.
How do I sign up for NCT05922878?
Contact the study team listed in the official ClinicalTrials.gov record.
About this trial
From the ClinicalTrials.gov record.
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Where it's running
| Site | City | State | Status |
|---|---|---|---|
| Site 200 | Phoenix | Arizona | Recruiting |
| Site 193 | Rogers | Arkansas | Recruiting |
| Site 218 | Bellflower | California | Recruiting |
| Site 335 | Lafayette | California | Recruiting |
| Site 335 | Lafayette | California | Recruiting |
| Site 219 | Mather | California | Recruiting |
| Site 267 | Moorpark | California | Recruiting |
| Site 197 | Temecula | California | Recruiting |
| Site 343 | Denver | Colorado | Recruiting |
| Site 221 | Tampa | Florida | Recruiting |
| Site 238 | Fayetteville | Georgia | Recruiting |
| Site 293 | Stone Mountain | Georgia | Not yet recruiting |
| Site 236 | Boise | Idaho | Recruiting |
| Site 288 | Worcester | Massachusetts | Recruiting |
| Site 240 | Mankato | Minnesota | Recruiting |
| Site 265 | Minneapolis | Minnesota | Recruiting |
| Site 264 | St Louis | Missouri | Recruiting |
| Site 344 | Las Vegas | Nevada | Recruiting |
| Site 114 | Albuquerque | New Mexico | Recruiting |
| Site 283 | New York | New York | Recruiting |
| Site 287 | Rose Hill | North Carolina | Recruiting |
| Site 268 | Winston-Salem | North Carolina | Recruiting |
| Site 202 | Cincinnati | Ohio | Recruiting |
| Site 316 | Austin | Texas | Recruiting |
| Site 239 | Conroe | Texas | Recruiting |
| Site 275 | Houston | Texas | Recruiting |
| Site 320 | Houston | Texas | Recruiting |
| Site 353 | Plano | Texas | Recruiting |
| Site 234 | San Marcos | Texas | Recruiting |
| Site 235 | Stephenville | Texas | Recruiting |
| Site 277 | Fairfax | Virginia | Recruiting |
Full eligibility criteria (from the record)
Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
Other recruiting trials: Depression clinical trials · Depression clinical trials in California · Depression (major depressive disorder) clinical trials · Depression (major depressive disorder) clinical trials in Texas
This listing shows only what the public ClinicalTrials.gov record NCT05922878 says, last updated there on 2026-10-26. It was checked against the registry on 22 November 2026. Taking part is voluntary, and the study team decides who is eligible. For the most current details, see the official record.